abiraterone acetate / Generic mfg. - LARVOL DELTA

QUEST: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P2 | N=136 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Phase classification: P1/2 ➔ P2

Phase classification • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CTCs

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), the NCCN Drugs & Biologics Compendium (NCCN Compendium), NCCN Guidelines Navigator, and the NCCN Radiation Therapy Compendium for Prostate Cancer, Version 1.2026. (NCCN)

NCCN guideline • Castration-Resistant Prostate Cancer

Impact of HRR Gene Subclass on Clinical Outcomes of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer. (PubMed, Clin Genitourin Cancer) - "Patients with mCRPC harboring effector HRR mutations derive greater clinical benefit from PARPi plus ARSi than those with sensor mutations. These findings highlight the heterogeneous predictive value of HRR gene alterations and suggest that mutation sub-class should guide treatment decisions in HRD-positive mCRPC."

Clinical data • Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ATM • BRCA1 • BRCA2 • CHEK1 • CHEK2 • FANCD2 • HRD • PALB2 • RAD51

Chimeric Antigen Receptor-Engineered (CAR)-T Cell Therapy for Metastatic Prostate Cancer. (PubMed, Cancer Lett) - "These include androgen receptor signaling inhibitors such as enzalutamide and abiraterone acetate, taxane-based chemotherapies including docetaxel and cabazitaxel, and bone-targeting radiopharmaceuticals like radium-223. Immunotherapeutic agents have also contributed to expanding treatment options with Sipuleucel-T, a dendritic cell-based vaccine, and pembrolizumab, a PD-1 immune checkpoint inhibitor approved for select patient populations. Furthermore, the introduction of poly (ADP-ribose) polymerase inhibitors like olaparib and rucaparib, has transformed the therapeutic landscape, particularly for patients with DNA repair deficiencies in metastatic prostate cancer...In this review, we highlight adoptive cellular therapies utilizing CAR-T cells engineered to recognize prostate cancer-specific antigens, aiming to overcome immune evasion mechanisms. We summarize current CAR-T modalities with their limitations and prospects being evaluated in both preclinical and clinical..."

Journal • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Neuroendocrine Tumor • Oncology • Prostate Cancer • Solid Tumor • DRD

SHIVA: A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer (clinicaltrials.gov) - P2 | N=742 | Completed | Sponsor: Institut Curie | Unknown status ➔ Completed

Trial completion • Oncology • Solid Tumor

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - P1/2 | N=54 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2025 ➔ Sep 2026 | Trial primary completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Olaparib Plus Abiraterone in HRR-Mutated Metastatic Hormone-Sensitive Prostate Cancer (ESMO 2025) - No abstract available

Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Germline BRCA2 Mutation and Lynch Syndrome in a Patient With Multiple Primary Malignancies. (PubMed, Case Rep Oncol Med) - "Treatment with androgen deprivation therapy with the addition of abiraterone and prednisone was initiated...The patient completed four cycles of cisplatin and gemcitabine, followed by the initiation of olaparib as per the POLE study...PARP inhibitors may be effective in controlling metastatic pancreatic cancer, and thus, genetic counseling is important for this patient and his family members, who will need appropriate cancer screening. The probability of carrying two pathogenic variants may be expected to increase as a result of next-generation sequencing and germline testing."

Journal • Brain Cancer • Genetic Disorders • Genito-urinary Cancer • Hepatology • Lung Cancer • Melanoma • Oncology • Pancreatic Cancer • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • BRCA • BRCA2 • PMS2

Breaking New Ground: PARPi + ARPi Combination Therapy in mCRPC (UAA 2025) - "PARPi, such as talazoparib, olaparib, and niraparib, target DNA damage repair pathways, particularly in tumors with homologous recombination repair (HRR) deficiencies. ARPi, including enzalutamide and abiraterone, inhibit androgen receptor signaling, a critical driver of prostate cancer progression...Similarly, the PROpel trial assessed olaparib combined with abiraterone acetate and prednisone (AAP), showing enhanced rPFS in both HRR-deficient and non-HRR-deficient populations...By leveraging the complementary mechanisms of these agents, this therapeutic strategy offers improved outcomes for patients with advanced prostate cancer. Continued research and clinical application will refine their use, ultimately enhancing the standard of care for mCRPC."

Combination therapy • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor • HRD

Breaking New Ground: PARPi + ARPi Combination Therapy in mCRPC (UAA 2025) - "PARPi, such as talazoparib, olaparib, and niraparib, target DNA damage repair pathways, particularly in tumors with homologous recombination repair (HRR) deficiencies. ARPi, including enzalutamide and abiraterone, inhibit androgen receptor signaling, a critical driver of prostate cancer progression...Similarly, the PROpel trial assessed olaparib combined with abiraterone acetate and prednisone (AAP), showing enhanced rPFS in both HRR-deficient and non-HRR-deficient populations...By leveraging the complementary mechanisms of these agents, this therapeutic strategy offers improved outcomes for patients with advanced prostate cancer. Continued research and clinical application will refine their use, ultimately enhancing the standard of care for mCRPC."

Combination therapy • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor • HRD

Efficacy of niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations identified by tissue vs plasma assay in MAGNITUDE study final analysis (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • HRD

Drug–Drug Interactions in Older Patients Treated with Abiraterone or Enzalutamide for Advanced Prostate Cancer: Results from the ADHERE Prospective Study (Meet-URO Network) (ESMO 2025) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Bone Fractures and Prior Abiraterone Use in Men Treated with Radium-223 and Enzalutamide Combination for Castration Resistant Prostate Cancer (CRPC) with Bone Metastases(m): A Real-World Observational Study (ESMO 2025) - No abstract available

Clinical • Observational data • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer (clinicaltrials.gov) - P=N/A | N=20 | Enrolling by invitation | Sponsor: Zhujiang Hospital

New trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase 3 study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281 (ESMO 2025) - No abstract available

Clinical • Metastases • P3 data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • PTEN

PROTRACT: PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (clinicaltrials.gov) - P2 | N=100 | Active, not recruiting | Sponsor: British Columbia Cancer Agency | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Apr 2025 ➔ Apr 2026 | Recruiting ➔ Active, not recruiting

Biomarker • Circulating tumor DNA • Enrollment closed • Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1/2 | N=44 | Active, not recruiting | Sponsor: Rahul Aggarwal | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2027 ➔ Jul 2027 | Trial primary completion date: Apr 2027 ➔ Jul 2027

Enrollment closed • Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

A Pain in the Rectum — But Not From the Colon (ACG 2025) - "He later developed osseous metastases and was transitioned to enzalutamide after abiraterone intolerance. His history was further complicated by pulmonary embolism and bilateral deep vein thromboses, managed with rivaroxaban...Immunohistochemistry is essential for accurate diagnosis and appropriate management. This case also highlights the value of multidisciplinary collaboration between gastroenterology, oncology, and pathology in complex diagnostic scenarios."

Colorectal Cancer • Fatigue • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain • Prostate Adenocarcinoma • Prostate Cancer • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • NKX3-1

Reassessing the Evidence: Is Intensified Therapy Justified in Older Patients with Metastatic Hormone-Sensitive Prostate Cancer? (PubMed, Clin Genitourin Cancer) - "Eligible studies combined androgen deprivation therapy (ADT) with docetaxel, abiraterone, enzalutamide, apalutamide, darolutamide, or antiandrogens. Treatment decisions in this population should be individualized using geriatric assessment, considering patient fitness, comorbidities, life expectancy, and treatment goals. Further dedicated trials in older and frail patients are warranted to guide optimal therapeutic strategies."

Journal • Review • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

PETRANHA: Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - P1/2 | N=175 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Apr 2031 ➔ Apr 2026 | Trial primary completion date: Apr 2031 ➔ Apr 2026

Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Low-Dose versus Standard-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer Post-Docetaxel: A Randomized Controlled Trial Protocol (DUMONT Trial) (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov) - P3 | N=1500 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Predicting Cardiovascular Risk in Patients with Prostate Cancer Receiving Abiraterone or Enzalutamide by Using Machine Learning. (PubMed, Cancers (Basel)) - " This machine learning approach identified five predictors of MACEs in PCa patients receiving ARPIs. These findings highlight the need for comprehensive cardiovascular risk assessment and vigilant monitoring in this patient population."

Journal • Cardiovascular • Congestive Heart Failure • Genito-urinary Cancer • Heart Failure • Hypertension • Myocardial Infarction • Oncology • Prostate Cancer • Solid Tumor

Comparative neurological safety of novel hormonal therapies in advanced prostate cancer: a Bayesian network meta-analysis of randomized trials. (PubMed, Int J Clin Oncol) - "Although no NHA significantly increased neurological AEs, enzalutamide showed the highest estimated risk, while darolutamide and NSAAs ranked best for neurological safety. Darolutamide may be preferred in elderly patients, highlighting the need for further long-term safety data."

Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Epilepsy • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Quality of Life Analysis in Patients with High-Risk Localized Prostate Cancer Receiving Neoadjuvant Pamiparib plus Abiraterone and ADT: A Prospective Study (ESMO 2025) - No abstract available

Clinical • HEOR • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor